LOS ANGELES, Nov 7 (Reuters) - Early results from an ongoing study showed that people with newly diagnosed rheumatoid arthritis were more likely to reach clinical remission with Amgen Inc and Wyeth's ...

Amsterdam – Rheumatoid arthritis patients who are on standard methotrexate therapy may benefit from the addition of the biologic treatment, ENBREL* (etanercept), according to new data from a one-year, ...

Amgen and Pfizer Announce Results From the Largest Completed Clinical Trial of a Biologic Therapy in Adults with Moderately Active RA THOUSAND OAKS, Calif. and NEW YORK, Nov. 5, 2011 /PRNewswire/ -- ...

The etanercept biosimilar, LBEC0101, demonstrated equivalent clinical efficacy and comparable safety profile to etanercept, and was well tolerated among patients with rheumatoid arthritis who failed ...

THOUSAND OAKS, Calif. and NEW YORK, May 25, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Pfizer Inc. (NYSE: PFE) today announced new results from multiple studies of ENBREL, further expanding the ...

SEATTLE, WA – Immunex Corporation (Nasdaq: IMNX) and Wyeth-Ayerst Laboratories, a division of American Home Products (NYSE: AHP) announced today that the U.S. Food and Drug Administration (FDA) has ...

Troubled Amgen Inc.'s good news with Enbrel at the American College of Rheumatology (ACR) meeting came with another shoe dropping in the trouble over its anemia drugs - the labels of which are ...

THOUSAND OAKS, Calif. and COLLEGEVILLE, Pa., Feb. 4, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) and Pfizer Inc. (NYSE: PFE) today announced results from a new trial that demonstrated Enbrel® ...

Amgen (NASDAQ:AMGN) today issued the following statement: Amgen today announced the issuance of U.S. Patent No. 8,063,182 related to Enbrel® (etanercept). This patent is owned by Hoffman-La Roche Inc.

Combining a new drug with the standard initial treatment for rheumatoid arthritis seems to work better than using either medicine alone, research indicates. About 1 percent of people have rheumatoid ...

The question invariably asked by every rheumatoid arthritis patient: Do I have to take these medications for the rest of my life? I do not know the answer to this question for any individual patient.

I just had an interesting experience with CVS Caremark. A few days ago, I saw a patient who had failed both Remicade® and Xeljanz® (she received the latter in a clinical trial at my practice). Given ...